Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Markets bet on defensive pharma
Tue, 8 Jul 01:30 pm

Indian share markets widened losses in the post-noon trading session. Barring pharma and FMCG, all the sectoral indices are trading in the red with metal and realty stocks being the biggest losers.

BSE-Sensex is down 97 points and NSE-Nifty is trading 43 points down. BSE Mid Cap is trading 0.7% down and BSE Small Cap index is trading down by 1.1%. The rupee is trading at 59.75 to the US dollar.

Most of the MNC pharma stocks are trading in the red with Merck and Novartis being the major losers whereas Abott India and Fulford India are trading in the green. As per a leading financial daily, Drug Controller General of India (DGCI) has asked multinational drug companies that want to conduct clinical trials for new drugs in India, to ensure an early launch of therapies in the country. The innovator drug companies will have to gain approval for new drugs in India after acquiring marketing clearance in their respective countries. Reportedly of the total 140 new drugs discovered and launched globally between 2006 and 2010, a mere 28% are available in the domestic markets. The gap is the sharpest in cancer treatment whereas in cardiovascular and neurology segments, the gap remains significant.

Majority of the power stocks are trading negative with GVK Power & Infra and JSW Energy being among major losers. The power minister has said that around 50% of India's coal-fired power plants have stocks that will last for a week. Majority of these power plants are in Maharashtra. Coal-fired power plants are likely to require 551.6 m tonnes of coal in FY15 but the supply will be limited to 466.9 m tonnes. The shortfall is likely to be met by coal imports. Falling hydro-electricity on weaker than average monsoon is likely to fuel further dependence on coal imports.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Markets bet on defensive pharma". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.